Archive for the ‘life extension’ category

Apr 13, 2024

Fresh Mitochondria as a Parkinson’s Treatment

Posted by in categories: biotech/medical, life extension, neuroscience

Scientists have tested a novel method of providing cells with healthy mitochondria to fight Parkinson’s disease [1].

Parkinson’s disease is the second-most prevalent neurodegenerative disorder, and it affects 10 million people worldwide. The disease is age-related, as its prevalence rises rapidly in people older than 65, although some people are diagnosed much earlier. Parkinson’s disease is characterized by both motor and mental problems: tremor, rigidity (stiffness), and slowness of movement along with memory and thinking deficits.

Parkinson’s disease is caused by the loss of dopamine-producing (dopaminergic) neurons in a brain region called the substantia nigra. Therapeutic options are limited, and some of the existing ones cause nasty side effects.

Apr 11, 2024

New study finds potential targets at chromosome ends for degenerative disease prevention

Posted by in categories: biotech/medical, genetics, life extension

We depend on our cells being able to divide and multiply, whether it’s to replace sunburnt skin or replenish our blood supply and recover from injury. Chromosomes, which carry all of our genetic instructions, must be copied in a complete way during cell division. Telomeres, which cap the ends of chromosomes, play a critical role in this cell-renewal process—with a direct bearing on health and disease.

Apr 11, 2024

Faster aging linked to cancer rates in young adults, study finds

Posted by in categories: biotech/medical, life extension

Researchers from Washington University School of Medicine suggest accelerated biological aging may be driving early-onset cancer rates in young people.

Apr 10, 2024

Dr. Phyllis Ferrell, DrPH, MBA — Chief Impact Officer, Alzheimer’s Moonshot, StartUp Health

Posted by in categories: biotech/medical, business, life extension, neuroscience

Is Chief Impact Officer for StartUp Health’s Alzheimer’s Moonshot (, a new global initiative created to develop a collaborative innovation community alongside leading companies, research teams, and stakeholders, with a mission to accelerate progress in prevention, diagnosis, and management of Alzheimer’s disease and related dementias. With support from the Alzheimer’s Drug Discovery Foundation (ADDF) and Gates Ventures, StartUp Health is looking to break down silos and foster meaningful collaboration between mission-aligned founders, funders, and partners.

Dr. Ferrell also serves as Strategic Advisor, Davos Alzheimer’s Collaborative (https://www.davosalzheimerscollaborat…) which is building a global clinical trial network and technology platform that will link trial sites around the world.

Continue reading “Dr. Phyllis Ferrell, DrPH, MBA — Chief Impact Officer, Alzheimer’s Moonshot, StartUp Health” »

Apr 10, 2024

Mechanisms of melanoma aggressiveness with age

Posted by in categories: biotech/medical, life extension

The extracellular matrix is an essential component of the tumor microenvironment and affects cancer progression. Weeraratna and colleagues have now uncovered that age-related reductions in the level of hyaluronan and proteoglycan link protein 1 (HAPLN1) stimulate neoangiogenesis and compromise the vascular integrity of intratumoral blood vessels. These biological modifications converge to fuel distant melanoma metastasis.

Apr 10, 2024

Step steady: Consistent walking improves brain function in older adults

Posted by in categories: biotech/medical, life extension, neuroscience


In a recent study published in the journal Scientific Reports, researchers explored how changes in daily step counts and variability affect cognitive function in older adults during a 10-week physical activity intervention.

Study: Association between changes in habitual stepping activity and cognition in older adults. Image Credit: SibRapid / Shutterstock.

Continue reading “Step steady: Consistent walking improves brain function in older adults” »

Apr 9, 2024

Could Tardigrades Have Colonized The Moon?

Posted by in categories: life extension, particle physics

First of all, they have to have survived the impact. Laboratory tests have shown that frozen specimens of the Hypsibius dujardini species travelling at 3,000 km/h in a vacuum were fatally damaged when they smashed into sand. However, they survived impacts of 2,600 km/h or less – and their “hard landing” on the Moon, unwanted or not, was far slower.

The Moon’s surface is not protected from solar particles and cosmic rays, particularly gamma rays, but here too, the tardigrades would be able to resist. In fact, Robert Wimmer-Schweingruber, professor at the University of Kiel in Germany, and his team have shown that the doses of gamma rays hitting the lunar surface were permanent but low compared with the doses mentioned above – 10 years’ exposure to Lunar gamma rays would correspond to a total dose of around 1 Gy.

But then there’s the question of “life” on the Moon. The tardigrades would have to withstand a lack of water as well as temperatures ranging from −170 to −190°C during the lunar night and 100 to 120°C during the day. A lunar day or night lasts a long time, just under 15 Earth days. The probe itself wasn’t designed to withstand such extremes and even if it hadn’t crashed, it would have ceased all activity after just a few Earth days.

Apr 7, 2024

Immune Checkpoint Discovery Has Implications for Treating Cancer and Autoimmune Diseases

Posted by in categories: biotech/medical, life extension

Your immune system should ideally recognize and attack infectious invaders and cancerous cells. But the system requires safety mechanisms, or brakes, to keep it from damaging healthy cells. To do this, T cells—the immune system’s most powerful attackers—rely on immune “checkpoints” to turn immune activation down when they receive the right signal. While these interactions have been well studied, a research team supported in part by NIH has made an unexpected discovery into how a key immune checkpoint works, with potentially important implications for therapies designed to boost or dampen immune activity to treat cancer and autoimmune diseases.1

The checkpoint in question is a protein called programmed cell death-1 (PD-1). Here’s how it works: PD-1 is a receptor on the surface of T cells, where it latches onto certain proteins, known as PD-L1 and PD-L2, on the surface of other cells in the body. When this interaction occurs, a signal is sent to the T cells that stops them from attacking these other cells.

Cancer cells often take advantage of this braking system, producing copious amounts of PD-L1 on their surface, allowing them to hide from T cells. An effective class of immunotherapy drugs used to treat many cancers works by blocking the interaction between PD-1 and PD-L1, to effectively release the brakes on the immune system to allow the T cells to unleash an assault on cancer cells. Researchers have also developed potential treatments for autoimmune diseases that take the opposite tact: stimulating PD-1 interaction to keep T cells inactive. These PD-1 “agonists” have shown promise in clinical trials as treatments for certain autoimmune diseases.

Apr 7, 2024

Resting Heart Rate, Heart Rate Variability: What’s Optimal, 2,061 Days of Data

Posted by in categories: genetics, life extension

Join us on Patreon! Links: Epigenetic, Telomere Testing:

Apr 6, 2024

‘Immortality protein’ within the mitochondria offers protection in myocardial infarction

Posted by in categories: biotech/medical, life extension

Year 2021 😗😁😘

Researchers Prof. Judith Haendeler from the Medical Faculty and the molecular biologist Prof. Joachim Altschmied from the Department of Biology, together with their teams, have shown for the first time in the cardiovascular system that telomerase reverse transcriptase (TERT) within the mitochondria, the powerhouses of the cells, has a protective function in myocardial infarction. This work, which was performed together with other groups from the University Hospital Düsseldorf and the University Hospital Essen within the frame of the Collaborative Research Center 1,116, was recently published in the journal Circulation.

Cardiac muscle cells benefit from the increased mitochondrial function and are protected from cell death. Other also profit from increased mitochondrial function such as fibroblasts, which are essential for stable scarring after an infarction, and , which are needed for vascularization and thus blood supply in the infarct area.

Continue reading “‘Immortality protein’ within the mitochondria offers protection in myocardial infarction” »

Page 1 of 60112345678Last